We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+37.57%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$343M
AUM Growth
+$89.3M
Cap. Flow
+$1.48M
Cap. Flow %
0.43%
Top 10 Hldgs %
98.93%
Holding
21
New
7
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$1.69M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$1.57M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$1.39M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$1.13M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$1.08M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$5.23M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$1.05M
3
INO icon
Inovio Pharmaceuticals
INO
+$754K
4
PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
+$160K
5
NRX
NEPHROGENEX INC COM
NRX
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 16.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$284M 82.63%
4,397,838
-91,200
-2% -$5.23M
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$25.5M 7.43%
11,294
– –
TOVX icon
3
Theriva Biologics
TOVX
$10.2M
$7.45M 2.17%
389
– –
ARCT icon
4
Arcturus Therapeutics
ARCT
$157M
$6.28M 1.83%
159,331
+35,715
+29% +$1.57M
LUMO
5
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$5.6M 1.63%
11,382
+2,778
+32% +$1.08M
ADXS
6
DELISTED
Advaxis Inc
ADXS
$3.97M 1.16%
18,333
+3,333
+22% +$512K
KERX
7
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.55M 0.74%
200,000
– –
ENLV icon
8
Enlivex Ltd
ENLV
$70.7M
$2.03M 0.59%
564
– –
ALDX icon
9
Aldeyra Therapeutics
ALDX
$91.7M
$1.38M 0.4%
+135,800
New +$1.39M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.23B
$1.21M 0.35%
+100,000
New +$1.13M
ADXSW
11
DELISTED
Advaxis Inc Warrants
ADXSW
$1.17M 0.34%
112,500
– –
ABEO icon
12
Abeona Therapeutics
ABEO
$345M
$669K 0.19%
+8,524
New +$686K
GLMD icon
13
Galmed Pharmaceuticals
GLMD
$3.94M
$612K 0.18%
361
– –
NBSE
14
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$521K 0.15%
+513
New +$1.69M
EVOK
15
DELISTED
Evoke Pharma
EVOK
$380K 0.11%
+374
New +$337K
ZSAN
16
DELISTED
Zosano Pharma Corporation
ZSAN
$202K 0.06%
+29
New +$218K
APTO
17
DELISTED
Aptose Biosciences, Inc.
APTO
$108K 0.03%
+44
New +$106K
INO icon
18
Inovio Pharmaceuticals
INO
$79.8M
– –
-6,841
Closed -$754K
PVCT
19
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
– –
-200,000
Closed -$160K
NRX
20
DELISTED
NEPHROGENEX INC COM
NRX
– –
-3,072
Closed -$41K
ASPX
21
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-20,000
Closed -$1.05M

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Knoll Capital Management held 21 positions worth $343M, up 35% from $254M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Knoll Capital Management's Q1 2015 filing shows 7 new, 3 increased, 1 reduced and 4 closed positions. Its largest new stake was NeuBase Therapeutics, Inc. Common Stock: 513 shares worth $521K. The largest sale was MEDIVATION, INC., an estimated $5.23M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 12% a quarter earlier.

  • Knoll Capital Management's largest Q1 2015 buy was NeuBase Therapeutics, Inc. Common Stock: 513 shares worth $521K.
  • Knoll Capital Management added most to Arcturus Therapeutics in Q1 2015, an estimated $1.57M increase.
  • Knoll Capital Management's biggest Q1 2015 reduction was MEDIVATION, INC., cutting an estimated $5.23M.
  • Knoll Capital Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2015, selling an estimated $1.05M.
  • Knoll Capital Management's ten largest holdings make up 99% of its $343M portfolio in Q1 2015.
  • Knoll Capital Management opened 7 new positions and closed 4 in Q1 2015.
  • Knoll Capital Management's portfolio value rose 35% quarter-over-quarter to $343M.

Based on Knoll Capital Management's 13F filing for Q1 2015, filed 15 May 2015.